Skip to main content
Premium Trial:

Request an Annual Quote

Healthlinx Signs $9M Financing Deal to Drive Expansion of OvPlex into US

Premium

This story originally ran on Dec. 14.

Australian diagnostics firm Healthlinx announced last week that it has inked a convertible note financing deal with California-based La Jolla Cove Investors for up to $9 million over four years.

Healthlinx will use the funds to move its protein biomarker-based ovarian cancer diagnostic OvPlex into the US, as well as accelerate expansion into other markets around the world, the company said in a statement.

“The company is particularly keen to enter the US market, and this funding will assist us to continue to work towards achieving this goal in a timely manner,” CEO Nick Gatsios added.

The US is by far the largest potential market for Healthlinx's OvPlex, representing a roughly $330 million market according to numbers provided by the company. In May, the company hired Aurora, Colo.-based CPC Clinical Research to help it prepare a pre-IDE submission to FDA and coordinate meetings between it and the agency.

Intellectual property concerns could complicate the company’s move into the US, however. A valuation of Healthlinx done in June by Australian consulting firm Acuity Technology Management noted that OvaCheck, an ovarian cancer diagnostic developed by now-defunct diagnostics firm Correlogic, includes three of the five proteins comprising the OvPlex panel. Given that Correlogic's OvaCheck patent was filed prior to Healthlinx's OvPlex patent, "there remains a risk that not all claims [related to OvPlex] will be granted in all jurisdictions," the Acuity report said.

Based on statements made by Healthlinx in a September shareholder update, it appeared the company was considering a purchase of Correlogic’s assets (PM 10/14/2011). This month, however, diagnostics firm Vermillion purchased Correlogic’s assets for $435,000 in cash (PM 12/2/2011).

Healthlinx launched OvPlex commercially in Australia in October 2008, expanding to the UK and Singapore in 2010 and to Malaysia in October of this year. Additionally, the company has distribution deals for the test in Israel, South Korea, India, Indonesia, Thailand, and Vietnam.

The La Jolla Cove funding will be provided in up to three notes of $3 million each. Each note will have a repayment term of four years with 4.75 percent interest payable monthly.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.